KEROS THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 58.76 USD | +1.56% |
|
+5.54% | +48.06% |
| 19/03 | Morphic Holding Names Simon Cooper as Chief Medical Officer | MT |
| 15/03 | Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug | MT |
Chart calendar Keros Therapeutics, Inc.
ba8108b02fe9641.zoOzsUjl1eWKaTo0vgIvAZbspporyefV3Mo4ZhScGu0.qq7jxA-coYzIOk8HzkNDU6a_9fdnutHsq55IUF3Nct6U8vneGdGNvOwufw~60ab31453982ab0bdffd4ef6fad51bb7
Upcoming events on Keros Therapeutics, Inc.
Past events on Keros Therapeutics, Inc.
| 13/03/2024 12:30 am | Leerink Partners Global Biopharma Conference |
| 29/02/2024 06:31 am | Q4 2023 Earnings Release |
| 12/12/2023 07:30 am | American Society of Hematology Meeting - Myeloproliferative Syndromes |
| 11/12/2023 06:30 pm | American Society of Hematology Meeting |
| 11/12/2023 07:30 am | American Society of Hematology Meeting - Myeloproliferative Syndromes |
| 11/12/2023 07:30 am | American Society of Hematology Meeting - Iron Homeostasis and Biology |
| 10/12/2023 07:30 am | American Society of Hematology Meeting - Iron Homeostasis and Biology |
| 10/12/2023 03:30 am | American Society of Hematology Meeting - MDS Clinical and Epidemiological |
| 30/11/2023 01:00 am | Piper Sandler Healthcare Conference |
| 15/11/2023 12:55 am | Stifel Healthcare Conference |
| 06/11/2023 06:30 pm | Q3 2023 Earnings Release |
| 04/10/2023 | World Muscle Society International Congress |
| 27/09/2023 11:20 pm | Cantor Global Healthcare Conference |
| 13/09/2023 08:30 pm | H.C. Wainwright Global Investment Conference |
| 12/09/2023 01:45 am | Morgan Stanley Global Healthcare Conference |
| 08/08/2023 05:30 pm | KER-012 Phase 2 Clinical Trial Results Call |
| 07/08/2023 09:30 pm | Q2 2023 Earnings Release |
| 14/06/2023 09:10 pm | Goldman Sachs Global Healthcare Conference |
| 09/06/2023 09:30 pm | European Hematology Association Hybrid Congress - Abstract No : P992 |
| 09/06/2023 09:30 pm | European Hematology Association Hybrid Congress - Abstract No : P1488 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 10,0 | 0,00 0,00 - | 20,1 0,10 20000% | 0,00 0,86 - | 0,15 0,00 3363.3% | 5,67 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | -169 -166 -1.88% | -180 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -46,7 -45,9 -1.62% | -56,4 -72,8 22.54% | -115 -112 -2.87% | -170 -167 -1.51% | -188 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -45,5 -46,7 2.59% | -56,7 -73,0 22.25% | -105 -103 -1.21% | -153 -154 0.81% | -178 |
|
Net income Million USD | Released Forecast Spread | 0,00 | -45,4 -47,3 4.05% | -58,7 -73,5 20.1% | -105 -104 -0.83% | -153 -154 0.87% | -175 |
|
EPS USD | Released Forecast Spread | -2,80 | -2,93 -4,15 29.31% | -2,52 -3,14 19.81% | -4,15 -4,16 0.34% | -5,20 -5,24 0.78% | -5,22 |
| Announcement Date | 27/02/20 | 25/03/21 | 09/03/22 | 03/03/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 20,0 0,00 - | 0,00 4,50 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,86 - | 0,00 0,22 - | 0,00 0,14 - | 0,00 0,00 - | 0,14 0,00 - | 0,00 | 0,00 | 0,00 | 6,28 | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -4,87 -21,3 77.13% | -24,1 -19,2 -25.63% | -30,7 -25,4 -21.06% | -28,0 -30,4 8.01% | -32,0 -28,7 -11.21% | -38,9 -31,3 -24.06% | -41,3 -39,7 -4.19% | -43,3 -42,1 -2.78% | -46,5 -44,5 -4.45% | -46,6 | -47,8 | -48,8 | -44,2 | -45,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -4,94 -21,2 76.67% | -24,2 -15,8 -53.41% | -27,3 -25,6 -6.39% | -23,5 -30,9 23.94% | -29,7 -28,4 -4.48% | -35,8 -31,1 -15.3% | -37,5 -39,5 5.16% | -39,4 -40,5 2.72% | -40,2 -42,5 5.3% | -44,1 | -44,8 | -46,2 | -42,8 | -41,6 |
|
Net income Million USD | Released Forecast Spread | -6,94 -21,7 68.03% | -24,2 -20,6 -17.22% | -27,3 -25,6 -6.66% | -23,5 -30,5 22.95% | -29,7 -28,8 -3.07% | -35,8 -31,3 -14.32% | -37,5 -38,9 3.71% | -39,4 -39,9 1.2% | -40,2 -42,2 4.64% | -43,6 | -44,2 | -45,6 | -41,1 | -41,6 |
|
EPS USD | Released Forecast Spread | -0,30 -0,92 67.3% | -1,01 -0,86 -17.1% | -1,13 -1,06 -6.81% | -0,92 -1,23 25.3% | -1,09 -1,10 0.65% | -1,26 -1,13 -11.34% | -1,27 -1,34 5.15% | -1,33 -1,35 1.32% | -1,34 -1,38 2.58% | -1,33 | -1,32 | -1,35 | -1,23 | -1,17 |
| Announcement Date | 09/03/22 | 05/05/22 | 04/08/22 | 03/11/22 | 03/03/23 | 04/05/23 | 07/08/23 | 06/11/23 | 28/02/24 | - | - | - | - | - |
More events
Past sector events for Keros Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- KROS Stock
- Calendar Keros Therapeutics, Inc.
